# Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

> **NCT05451173** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Alexander Chi** · enrollment: 83 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Non-small Cell Carcinoma
- Non-small Cell Lung Cancer Stage I
- Non-small Cell Lung Cancer Stage II
- Non-small Cell Lung Cancer Stage III

## Interventions

- **RADIATION:** Stereotactic body radiotherapy
- **RADIATION:** Hypofractionated radiotherapy
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05451173
- **Lead sponsor:** Alexander Chi
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-09
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05451173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05451173, "Combining ICI With SBRT or HypoFrx-RT for ES NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05451173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*